Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
HIV Seropositivity: HELP
Articles from South Yorkshire
Based on 4 articles published since 2008
||||

These are the 4 published articles about HIV Seropositivity that originated from South Yorkshire during 2008-2019.
 
+ Citations + Abstracts
1 Review Systematic review of the performance of HIV viral load technologies on plasma samples. 2014

Sollis, Kimberly A / Smit, Pieter W / Fiscus, Susan / Ford, Nathan / Vitoria, Marco / Essajee, Shaffiq / Barnett, David / Cheng, Ben / Crowe, Suzanne M / Denny, Thomas / Landay, Alan / Stevens, Wendy / Habiyambere, Vincent / Perrins, Jos / Peeling, Rosanna W. ·Department of Clinical Research, London School of Hygiene & Tropical Medicine, London, United Kingdom. · Department of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, United States of America. · Department of HIV/AIDS, World Health Organization, Geneva, Switzerland. · HIV, Medicine and Science, Clinton Health Access Initiative, New York, New York, United States of America. · Department of Haematology, United Kingdom National External Quality Assessment Service (UK NEQAS) for Leucocyte Immunophenotyping, Sheffield, United Kingdom. · Department of Technology and Innovation, Pangaea Global AIDS Foundation, San Fransisco, California, United States of America. · Centre for Biomedical Research, Burnet Institute, Melbourne, Australia. · Department of Medicine, Duke Human Vaccine Institute and Center for HIV/AIDS Vaccine Immunology, Durham, North Carolina, United States of America. · Department of Immunology- Microbiology, Rush University Medical Center, Chicago, Illinois, United States of America. · Department of Molecular Medicine and Haematology, University of the Witwatersrand, Johannesburg, South Africa. ·PLoS One · Pubmed #24558359.

ABSTRACT: BACKGROUND: Viral load (VL) monitoring is the standard of care in developing country settings for detecting HIV treatment failure. Since 2010 the World Health Organization has recommended a phase-in approach to VL monitoring in resource-limited settings. We conducted a systematic review of the accuracy and precision of HIV VL technologies for treatment monitoring. METHODS AND FINDINGS: A search of Medline and Embase was conducted for studies evaluating the accuracy or reproducibility of commercially available HIV VL assays. 37 studies were included for review including evaluations of the Amplicor Monitor HIV-1 v1.5 (n = 25), Cobas TaqMan v2.0 (n = 11), Abbott RealTime HIV-1 (n = 23), Versant HIV-1 RNA bDNA 3.0 (n = 15), Versant HIV-1 RNA kPCR 1.0 (n = 2), ExaVir Load v3 (n = 2), and NucliSens EasyQ v2.0 (n = 1). All currently available HIV VL assays are of sufficient sensitivity to detect plasma virus levels at a lower detection limit of 1,000 copies/mL. Bias data comparing the Abbott RealTime HIV-1, TaqMan v2.0 to the Amplicor Monitor v1.5 showed a tendency of the Abbott RealTime HIV-1 to under-estimate results while the TaqMan v2.0 overestimated VL counts. Compared to the Amplicor Monitor v1.5, 2-26% and 9-70% of results from the Versant bDNA 3.0 and Abbott RealTime HIV-1 differed by greater than 0.5log10. The average intra and inter-assay variation of the Abbott RealTime HIV-1 were 2.95% (range 2.0-5.1%) and 5.44% (range 1.17-30.00%) across the range of VL counts (2log10-7log10). CONCLUSIONS: This review found that all currently available HIV VL assays are of sufficient sensitivity to detect plasma VL of 1,000 copies/mL as a threshold to initiate investigations of treatment adherence or possible treatment failure. Sources of variability between VL assays include differences in technology platform, plasma input volume, and ability to detect HIV-1 subtypes. Monitoring of individual patients should be performed on the same technology platform to ensure appropriate interpretation of changes in VL. Prospero registration # CD42013003603.

2 Review Evolving controversies and challenges in the management of opportunistic infections in HIV-seropositive individuals. 2011

Dockrell, David H / Edwards, Simon / Fisher, Martin / Williams, Ian / Nelson, Mark. ·Department of Infection and Immunity, The University of Sheffield Medical School, Beech Hill Rd, Sheffield S10 2RX, UK; Sheffield Teaching Hospitals, UK. d.h.dockrell@sheffield.ac.uk ·J Infect · Pubmed #21664932.

ABSTRACT: The British HIV Association, in association with the British Infection Association, has produced guidelines on the management of opportunistic infections in individuals living with HIV. Opportunistic infections remain a major clinical challenge emphasising the key role of early testing and getting individuals on antiretroviral therapy before their CD4 T-cell count drops to levels that put individuals at risk of opportunistic infection. We emphasise the changing pattern of opportunistic infections and the importance of considering what constitutes an opportunistic infection in the era of effective combination antiretroviral therapy as well as the increasing burden of geographically restricted infections. Key areas of when to safely stop prophylaxis against opportunistic infection and when to start antiretroviral therapy after treatment of an opportunistic infection are discussed.

3 Review Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature. 2009

Collini, P / Premchand, N / Lockwood, D / Greig, J. ·University of Sheffield School of Medicine and Biomedical Sciences, Royal Hallamshire Hospital, Sheffield S10 2JF, UK. p.collini@sheffield.ac.uk ·Ann Trop Med Parasitol · Pubmed #19583915.

ABSTRACT: -- No abstract --

4 Article Comparison of methodological data measurement limits in CD4⁺ T lymphocyte flow cytometric enumeration and their clinical impact on HIV management. 2013

Whitby, Liam / Whitby, Alison / Fletcher, Matthew / Helbert, Matthew / Reilly, John T / Barnett, David. ·UK NEQAS for Leucocyte Immunophenotyping, 4th Floor, Pegasus House, 463a Glossop Road, Sheffield S10 2QD, United Kingdom. liam.whitby@ukneqasli.co.uk ·Cytometry B Clin Cytom · Pubmed #23788473.

ABSTRACT: UK NEQAS for Leucocyte Immunophenotyping, an ILAC G13:2000 accredited External Quality Assessment (EQA) organization, with over 3000 international laboratories participating in 14 programmes, issues 2 proficiency testing samples of stabilized whole blood to 824 participants in the Immune Monitoring (lymphocyte subset) programme every two months. We have undertaken a study of 58,626 flow cytometric absolute CD4⁺ T lymphocyte count data sets from these laboratories over a 12-year-period (2001-2012) to determine counting method variation in data measurement limits and how this could influence the clinical management of HIV patients. Comparison of relative error and 99.9% confidence limits for absolute CD4⁺ T lymphocyte values was undertaken using dual platform (DP) and single platform (SP) data and showed that the SP consistently outperformed DP, giving lower relative errors and confidence limits at clinically significant absolute CD4⁺ T lymphocyte counts. Our data shows that absolute CD4⁺ T lymphocyte counts should be obtained using single platform technology to reduce the variability at clinically relevant levels. On data where results (irrespective of platform) were below the international treatment threshold of 350 cells/μl, there was no significant misclassification between either SP or DP techniques meaning most patients would receive the correct treatment at the correct time. However, results that were above the treatment level of 350 cells/μl had a significant difference (P = 0.04) between DP and SP platforms, suggesting patients monitored using DP technology were 20% more likely to start therapy prematurely than those monitored with SP technology.